CB-668 / Calithera - LARVOL DELTA

Single Cell Analysis Identifies Immune Marker IL4I1 As Critical for Leukemogenesis and Immunity (ASH 2022) - "Finally, we tested IL4I1 expression in response to Fedratinib, a JAK2 inhibitor, and showed that IL4I1 expression was decreased in responders (R) vs nonresponders (NR) (Fig. 2F). We conclude that IL4I1 is a rational immune therapeutic target for AML and testing of IL4I1 Inhibitor CB-668 through a collaboration with Calithera is underway."

IO biomarker • Acute Myelogenous Leukemia • Brain Cancer • CNS Tumor • Glioma • Hematological Malignancies • Immunology • Inflammation • Leukemia • Oncology • Solid Tumor • ANXA5 • CD34 • CD8 • IL4 • PRKDC

[VIRTUAL] Anti-tumor activity of CB-668, a potent, selective and orally bioavailable small-molecule inhibitor of the immuno-suppressive enzyme Interleukin 4 (IL-4)-Induced Gene 1 (IL4I1) (SITC 2020) - "CB-668 also favorably combined with anti-PD-L1 therapy to reduce tumor growth in the B16-F10 tumor model. Conclusions These data support an immune-mediated anti-tumor effect of IL4I1 inhibition by CB-668, and suggest inhibition of IL4I1 represents a novel strategy for cancer immuno-therapy."

IO Biomarker • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Ovarian Cancer • Solid Tumor • CD8 • IL4

[VIRTUAL] Anti-tumor activity of CB-668, a potent, selective and orally bioavailable small-molecule inhibitor of the immuno-suppressive enzyme Interleukin 4 (IL-4)-Induced Gene 1 (IL4I1) (SITC 2020) - "CB-668 also favorably combined with anti-PD-L1 therapy to reduce tumor growth in the B16-F10 tumor model. Conclusions These data support an immune-mediated anti-tumor effect of IL4I1 inhibition by CB-668, and suggest inhibition of IL4I1 represents a novel strategy for cancer immuno-therapy."

IO Biomarker • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Ovarian Cancer • Solid Tumor • CD8 • IL4

Calithera Biosciences Presents New Preclinical Data for CB-668 at Society for Immunotherapy of Cancer (SITC) 2020 Annual Meeting (GlobeNewswire) - “Calithera Biosciences, Inc…announced that new preclinical data for the company’s novel IL4I1 inhibitor CB-668 will be presented at the Society for Immunotherapy of Cancer (SITC) Virtual Annual Meeting 2020….The preclinical data being presented by Andrew MacKinnon, Ph.D., demonstrate that CB-668 is a potent and selective inhibitor of IL4I1, exhibiting immune-mediated, single agent activity in syngeneic mouse tumor models. CB-668 was well-tolerated at efficacious doses in animal studies. In addition, CB-668 augments checkpoint inhibitors in these models.”

Preclinical • Oncology